Michael U. Callaghan

4.9k total citations · 3 hit papers
101 papers, 3.2k citations indexed

About

Michael U. Callaghan is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Michael U. Callaghan has authored 101 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Hematology, 40 papers in Genetics and 13 papers in Molecular Biology. Recurrent topics in Michael U. Callaghan's work include Hemophilia Treatment and Research (36 papers), Hemoglobinopathies and Related Disorders (24 papers) and Platelet Disorders and Treatments (23 papers). Michael U. Callaghan is often cited by papers focused on Hemophilia Treatment and Research (36 papers), Hemoglobinopathies and Related Disorders (24 papers) and Platelet Disorders and Treatments (23 papers). Michael U. Callaghan collaborates with scholars based in United States, Switzerland and Italy. Michael U. Callaghan's co-authors include Rebecca Kruse‐Jarres, Johnny Mahlangu, Gallia G. Levy, Johannes Oldenburg, Midori Shima, Elina Asikanius, Christophe Schmitt, Claude Négrier, Guy Young and Elena Santagostino and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Michael U. Callaghan

98 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

2017 759 citations Johannes Oldenburg, Johnny Mahlangu et al. profile →
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

2018 503 citations Johnny Mahlangu, Johannes Oldenburg et al. profile →
UPR Pathways Combine to Prevent Hepatic Steatosis Caused by ER Stress-Mediated Suppression of Transcriptional Master Regulators

2008 480 citations Michael U. Callaghan, Randal J. Kaufman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael U. Callaghan United States	24	2.1k	824	577	457	403	101	3.2k
Linda Fletcher Australia	31	1.5k 0.7×	1.2k 1.4×	369 0.6×	130 0.3×	912 2.3×	84	2.9k
Håkon Reikvam Norway	32	1.5k 0.7×	406 0.5×	1.3k 2.3×	84 0.2×	227 0.6×	180	3.0k
Constantino Martı́nez Spain	33	891 0.4×	250 0.3×	985 1.7×	148 0.3×	142 0.4×	101	2.8k
M Bourel France	26	1.3k 0.6×	842 1.0×	403 0.7×	81 0.2×	442 1.1×	104	2.7k
A. Victor Hoffbrand United Kingdom	31	1.2k 0.6×	727 0.9×	794 1.4×	76 0.2×	189 0.5×	100	2.9k
Anastasios G. Kriebardis Greece	26	628 0.3×	344 0.4×	681 1.2×	267 0.6×	99 0.2×	96	2.4k
Mammen Chandy India	32	2.0k 1.0×	673 0.8×	1.0k 1.8×	39 0.1×	176 0.4×	156	2.9k
A. Phillip Owens United States	27	766 0.4×	197 0.2×	893 1.5×	93 0.2×	355 0.9×	55	3.1k
Erica Sparkenbaugh United States	21	497 0.2×	393 0.5×	467 0.8×	237 0.5×	124 0.3×	43	1.5k
A. Victor Hoffbrand United Kingdom	30	1.2k 0.6×	990 1.2×	666 1.2×	63 0.1×	103 0.3×	81	2.5k

Countries citing papers authored by Michael U. Callaghan

Since Specialization

Citations

This map shows the geographic impact of Michael U. Callaghan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael U. Callaghan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael U. Callaghan more than expected).

Fields of papers citing papers by Michael U. Callaghan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael U. Callaghan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael U. Callaghan. The network helps show where Michael U. Callaghan may publish in the future.

Co-authorship network of co-authors of Michael U. Callaghan

This figure shows the co-authorship network connecting the top 25 collaborators of Michael U. Callaghan. A scholar is included among the top collaborators of Michael U. Callaghan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael U. Callaghan. Michael U. Callaghan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Callaghan, Michael U., et al.. (2022). Targeting TRPV1 activity via high‐dose capsaicin in patients with sickle cell disease. SHILAP Revista de lepidopterología. 3(3). 653–659. 4 indexed citations

Hulbert, Monica L., Deepa Manwani, Emily Riehm Meier, et al.. (2022). Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease center. Pediatric Blood & Cancer. 70(1). e29961–e29961. 13 indexed citations

Coyne, Karin S., Brooke M. Currie, Michael U. Callaghan, et al.. (2022). Validation of patient‐reported vaso‐occlusive crisis day as an endpoint in sickle cell disease studies. European Journal Of Haematology. 109(3). 226–237. 2 indexed citations

Skinner, Mark W., Claude Négrier, Ido Paz‐Priel, et al.. (2021). The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia. 27(5). 854–865. 34 indexed citations

Callaghan, Michael U., et al.. (2021). Longitudinal assessment of adhesion to vascular cell adhesion molecule‐1 at steady state and during vaso‐occlusive crises in sickle cell disease. British Journal of Haematology. 196(4). 1052–1058. 2 indexed citations

Minniti, Caterina P., Ahmar U. Zaidi, Mehdi Nouraie, et al.. (2021). Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection. Blood Advances. 5(1). 207–215. 51 indexed citations

Hines, Patrick C., et al.. (2021). Flow adhesion of whole blood to P‐selectin: a prognostic biomarker for vaso‐occlusive crisis in sickle cell disease. British Journal of Haematology. 194(6). 1074–1082. 9 indexed citations

Bartolucci, Pablo, Kenneth I. Ataga, Michael U. Callaghan, et al.. (2021). Trial in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase Ib CROSSWALK-a Trial Evaluating the Safety of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOEs) in Patients with Sickle Cell Disease (SCD). Blood. 138(Supplement 1). 3108–3108. 6 indexed citations

Callaghan, Michael U., Claude Négrier, Ido Paz‐Priel, et al.. (2020). Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 137(16). 2231–2242. 170 indexed citations

10.

Stevens, Brett M., Courtney L. Jones, Michael U. Callaghan, et al.. (2020). ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes. JCI Insight. 5(18). 18 indexed citations

11.

Callaghan, Michael U., Claude Négrier, Ido Paz‐Priel, et al.. (2020). Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4). Blood. 136(Supplement 1). 3–5. 4 indexed citations

12.

Xi, Yue, Justin Miller, Qinghua Zeng, et al.. (2019). Disulfiram (Antabuse) Activates ROS-Dependent ER Stress and Apoptosis in Oral Cavity Squamous Cell Carcinoma. Journal of Clinical Medicine. 8(5). 611–611. 34 indexed citations

13.

Oldenburg, Johannes, Johnny Mahlangu, Ido Paz‐Priel, et al.. (2019). Emicizumab Prophylaxis Administered Once-weekly or Every Two Weeks Provides Effective Bleed Prevention in Persons with Hemophilia A (PwHA) without Inhibitors - Results from the Phase III HAVEN 3 Study. Hämostaseologie. 39. 2 indexed citations

14.

Callaghan, Michael U., Benjamin Trzaskoma, Richard H. Ko, et al.. (2019). Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience. Blood. 134(Supplement_1). 2395–2395. 5 indexed citations

15.

Sharma, Deva, Mark Rodeghier, Djamila L. Ghafuri, et al.. (2019). Acute Vaso-Occlusive Pain is Temporally Associated with the Onset of Menstruation in Women with Sickle Cell Disease. Journal of Women s Health. 28(2). 162–169. 25 indexed citations

16.

Malec, Lynn, Stacy E. Croteau, Michael U. Callaghan, et al.. (2019). Spontaneous Bleeding and Poor Bleeding Response with Extended Half-Life Factor IX Products: A Survey of Select US and Canadian Hemophilia Treatment Centers. Blood. 134(Supplement_1). 2407–2407. 6 indexed citations

17.

Daak, Ahmed, Carlton Dampier, Beng Fuh, et al.. (2018). Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial). Blood Advances. 2(15). 1969–1979. 31 indexed citations

18.

Mancuso, Maria Elisa, Michael U. Callaghan, Rebecca Kruse‐Jarres, et al.. (2017). Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study. Blood. 130. 1071–1071. 14 indexed citations

19.

Kruse‐Jarres, Rebecca, Michael U. Callaghan, Stacy E. Croteau, et al.. (2017). Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2). Blood. 130(Suppl_1). 89–89. 43 indexed citations

20.

Agarwal, K N, Jacob Puliyel, Pramod Upadhyay, et al.. (2001). International child health. Archives of Disease in Childhood. 84(90001). 43a–44. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact